About this item:

111 Views | 110 Downloads

Author Notes:

Dennis C. Liotta, Email: dliotta@emory.edu.

The authors would like to thank Kevin Ogden and Frank Menniti for their critical feedback and helpful suggestions.

Some of the authors (RMS, TMA, SSZ, SFT, DCL) are inventors on Emory-owned IP involving NMDA receptor ligands.

Some of the authors have an equity position (SFT, DCL), are Board members (DCL), or paid consultants (SFT) for NeurOp Inc., which is developing NMDA receptor modulators for the treatment of neurological disease.

Subjects:

Research Funding:

This work was supported by the NIH-NINDS(NS071802 TMA, NS065371, NS036654 SFT) and NIH Graduate training in the Pharmacological Sciences [GM008602 TMA].

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Chemistry, Medicinal
  • Pharmacology & Pharmacy
  • channel blocker
  • deuterated analogs
  • glycine site antagonist
  • NMDA receptor antagonist
  • NMDA receptor potentiator
  • NMDA receptor subunit selectivity
  • METHYL-D-ASPARTATE
  • POSITIVE ALLOSTERIC MODULATORS
  • TRAUMATIC BRAIN-INJURY
  • AMINO-TERMINAL DOMAIN
  • D-CYCLOSERINE
  • CLINICAL-TRIALS
  • GLYCINE-SITE
  • NONCOMPETITIVE INHIBITION
  • MOLECULAR DETERMINANTS
  • PREGNENOLONE SULFATE

Novel NMDA Receptor Modulators: An Update

Tools:

Journal Title:

Expert Opinion on Therapeutic Patents

Volume:

Volume 22, Number 11

Publisher:

, Pages 1337-1352

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Introduction: The NMDA receptor is a ligand-gated ion channel that plays a critical role in higher level brain processes and has been implicated in a range of neurological and psychiatric conditions. Although initial studies for the use of NMDA receptor antagonists in neuroprotection were unsuccessful, more recently, NMDA receptor antagonists have shown clinical promise in other indications such as Alzheimer's disease, Parkinson's disease, pain and depression. Based on the clinical observations and more recent insights into receptor pharmacology, new modulatory approaches are beginning to emerge, with potential therapeutic benefit. Areas covered: The article covers the known pharmacology and important features regarding NMDA receptors and their function. A discussion of pre-clinical and clinical relevance is included, as well. The subsequent patent literature review highlights the current state of the art targeting the receptor since the last review in 2010. Expert opinion: The complex nature of the NMDA receptor structure and function is becoming better understood. As knowledge about this receptor increases, it opens up new opportunities for targeting the receptor for many therapeutic indications. New strategies and advances in older technologies will need to be further developed before clinical success can be achieved. First-in-class potentiators and subunit-selective agents form the basis for most new strategies, complemented by efforts to limit off-target liability and fine-tune on-target properties.

Copyright information:

© 2012 Informa UK Limited

Export to EndNote